MSI Bioscience S.A. Investor Presentation - Warsaw, 2015 - Breakthrough in Oral Cancer Detection

MSI Bioscience S.A.

  Breakthrough in Oral Cancer Detection

Investor Presentation – Warsaw, 2015

Safe Harbor
Certain of the statements and the projections set forth in this presentation
constitute “forward-looking statements.” Forward-looking statements include,
without limitation, any statement that may predict, forecast, indicate, or imply
future results, performance or achievements, and may contain the words
“estimate,” “project,” “intend,” “forecast,” “anticipate,” “plan,” “planning,”
“expect,” “believe,” “will,” “will likely,” “should,” “could,” “would,” “may” or words
or expressions of similar meaning. All such forward-looking statements involve
risks and uncertainties, including but not limited to the factors set forth in the Risk
Factors section of this presentation and to the particular risks inherent in any
development stage company that has developed new products for which it has not
yet demonstrated market acceptance or generated any historical sales.

Prospective investors are cautioned that there also can be no assurance that the
forward-looking statements included in this presentation will prove to be accurate.
In light of the significant uncertainties inherent in the forward-looking statements
included herein, the inclusion of such information should not be regarded as a
representation or warranty by us or any other person that our objectives and plans
will be achieved in any specified timeframe, if at all. Except to the extent required
by applicable laws or rules, we do not undertake any obligation to update any
forward-looking statements or to announce revisions to any of the forward-looking
statements.

                                           2

Company Highlights
 A breakthrough in the fight against oral cancer

 Patent pending technology surrounding the system for the early detection of
  oral cancer for dental applications

 Planned submission for CE certification and FDA approval of MSI system

 Disposables create high-margin recurring-revenue model

 Highly scalable business utilizing outsourced production & distribution model

                                         3

Market Overview
 Increased worldwide incidence of oral cancers from tobacco, alcohol and
  HPV virus
   • 36,000 cases of oral cavity or oropharyngeal cancer in the USA in 2013
   • 8,400 cases caused by oral HPV infection*
 Global dental equipment market is expected to reach $7.1 billion in 2019
  from $5.4 billion in 2014 according to Transparency Market Research, a
  market intelligence company based in the U.S.
 Dental market encompasses over 180,000 dentists in the USA and over
  330,000 dentists in the European Union
 Dentists in U.S. are expected to adopt more and newer adjunctive devices
  for oral cancer detection
   • To take advantage of insurance reimbursement and existing billing codes
   • To earn an additional $20,000 in revenue per year

* American Cancer Society
                                        4

Company Overview
 A medical device company committed to commercializing innovative
  systems for the early detection of cancer
 MSI Bioscience S.A holds the exclusive worldwide exclusive license
  rights, by its subsidiary MSI Bioscience Sp. z o.o, for the intellectual
  property of the Multispectral Imaging System for the early detection of
  oral and other cancers
 Sophisticated diagnostic algorithms in less than one second analyze the
  high definition images of 18 different narrow band wavelengths of light
  to distinguish benign from suspicious lesions

                                    5

MSI Camera
 Sophisticated diagnostic algorithm
    • Real time, quick (less than 1 second)
      verification process of high definition images
    • Expected to provide superior early stage oral
      cancer detection results
 Low cost, hand held, portable device
    • Small enough to analyze back of throat where the HPV virus lives
 Valuable tool for telemedicine
    • Dentist can enter and save patient data for monitoring and share
      with colleagues
    • Connected to a laptop via USB cable or by the application for smart
      phones and tablets

                                       6

Multispectral Imaging Technology
 Multispectral imaging technology
    • Developed by scientists at the British Columbia Cancer Agency
    • Filed for patent protection in over 10 jurisdictions and the Patent
      Cooperation Treaty (PCT) application is now in the final, national
      and regional phase
 Multispectral imaging system
    • Takes high definition images of 18 different narrow band
      wavelengths of light
    • Extracts a broad spectrum of data invisible to the human eye –
      tissue oxygenation ratios, hemoglobin levels and scatter size etc

                                     7

Comparison To Examination Lights
 Majority of dentists still rely on a visual examination for oral screening using
  normal white light examination lights
      Results in missing oral cancers which are difficult to see
      Some dentists use a fluorescent examination light (i.e. Velscope)
 Drawbacks:
    • Simply illuminating the oral cavity with one wavelength of blue/greenlight
    • Causes an autofluorescence effect, resulting in a very high rate of false
      positives
    • Oral cancer caused by HPV virus is very hard to detect with this method

                                             8

Competitive Advantages
 Competition for MSI system to detect early stages of oral cancers are
  one or two wave length examination lights such as Identafi, VELscope
  and Vizilite
 MSI camera has several clear advantages over the competing products
  and provides superior sensitivity and accuracy:

                                    9

Successful Product Track Record
 Verisante's platform based on Raman Spectroscopy operating software and
  probe technology is fully extensible to early detection systems for other cancer
  types
     Developed and patented by BC Cancer Agency and scientists of University
      of British Columbia and validated by clinicians at Vancouver General
      Hospital
     Verisante Aura™ device for early stage skin cancer detection – marketed in
      Canada and Europe, approved for sale in Australia and Mexico, waiting for
      approval to sale in USA
         • 2014 North American Technology Innovation of the Year Award for In
           Vivo Cancer Detection by Frost & Sullivan
         • Popular Science Magazine’s “Best of What’s New Award” for 2011
         • 2013 Prism Award for Innovation in Photonics
         • 2013 Edison Award for Excellence in Innovation
     Verisante Core™ device for lung, colon and cervical cancer detection
         • one of the top 10 cancer breakthroughs of 2011 by the Canadian
           Cancer Society
                                        10

Licensing Agreement
 Under the Letter of Intent, signed between Astoria Capital S.A (“ACL”)
  and Verisante Technology, Inc. (“VRS”) in May 2014:
   • ACL and Thomas Braun formed joint venture named MSI Bioscience
     Sp z.o.o (“MB”) with respectively 70% and 30% in total equity
   • VRS will provide MB with worldwide exclusive technology rights for
     design, development and commercialization of the instrument for
     the early detection of oral cancer
   • MB will pay to VRS a 3% royalty on any instruments sold

                                   11

Product Development

  Product                                  CE Regulatory     Commercial
                    Clinical Study          Submission         Launch
Development

Prototype            Complete by            Complete by        Expected by
Complete in          2017                   2017               2018
2016

              Sign up independent global distributors (UNDERWAY)

                                      12

Regulatory Process

      Europe              United States      Commercialization
• European             • Multispectral       • Commercialization
  regulatory (CE)        Imaging System is     of the instrument
  submission for         planned to be         after obtaining a
  approval on the        submitted for FDA     regulatory
  instrument for         approval in 2019      approval for
  early detection of                           instrument in
  oral cancer is                               either US or EU
  planned in 2017

                                  13

Warsaw Listing
 MSI Bioscience Sp. z o.o. completed reverse merger transaction
  with Jantar Development S.A. – company listed on the
  NewConnect market of the Warsaw Stock Exchange. After
  transaction Jantar Development S.A. changed name to MSI
  Bioscience S.A.
 Plans to uplist to Main Market of the Warsaw Stock Exchange
  (2016) and dual-list in the United States (2017).

                                14

Summary
 MSI Bioscience Sp. z o.o, the subsidiary of MSI Bioscience S.A. will hold the
  exclusive worldwide rights to develop and commercialize the Multispectral
  Imaging “MSI” System

 A breakthrough in the fight against oral cancer

 Patent pending technology surrounding the system for the early detection of
  oral cancer for dental applications

 Planned submission for CE certification and FDA approval of MSI system

 Highly scalable business utilizing outsourced production & distribution model

                                         15

Appendix – Company Snapshot

MSI Bioscience S.A.        Highlights

Stock Exchange             WSE – NewConnect

Ticker Symbol              MSI

Shares Outstanding         5,000,000

                           1,650,000 PLN
Market Cap
                           (450,000 USD)

Fiscal Year End            Dec 31

                      16

MSI Bioscience S.A.

       Breakthrough in Oral Cancer Detection

MSI Bioscience S.A               David K. Waldman
Plac Powstancow Slaskich 1/201   Crescendo Communications Europe Sp. z o.o.
53-329 Wroclaw, Poland           Tel : +1-212-671-1021
                                 e-mail: msi@crescendo-ir.com
Thank You!